Approvals and New Campaigns Introduced in the Q4 2025 EU Lung Cancer Market

CStone Pharmaceuticals announced a positive CHMP opinion and subsequent approval for Cejemly as a monotherapy treatment for unresectable non-small cell lung cancer.

A press release touted the EU approval of subcutaneous Keytruda based on results from the 3475A-D77 study. The “Chance” campaign was also introduced in Germany as MSD advertised the brand’s efficacy, safety, MCBS “A” score, and ten years of use.

Roche announced its financial results for part of 2025, Tecentriq’s FDA approval in combination with lurbinectedin for ES-SCLC, and the presentation of data at the 2025 ESMO conference. The “Look Closely” campaign was also utilized as materials promoted the brand’s appropriate patient types and benefits.

The HCP “Look Ahead” theme premiered in materials marketing Tevimbra’s approval for the perioperative treatment of non-small cell lung cancer, nine indications, efficacy, safety, and cost effectiveness. BeOne Medicines also advertised the brand’s new 400 mg formulation, recommended dosing, and national code number in Spain.